Exclusive Videos

Exclusive Videos

video

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...
video

Ruxolitinib in CMML: Study Shows Promising Results

Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with...
video

Options for Treating the High-Risk APL Patient

Alan Burnett, MD, takes a look at the combination of ATRA + ATO + GO in high-risk acute promyelocytic leukemia (APL) patients, the complications...
video

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more...
video

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory...
Advertisement

Current Issue

July Bonus Mid-Year Edition

This bonus issue features conversations with families joined by hematology, highlights from recent hematology/oncology meetings, and more.